Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis

e11531 Background: There is a need to perform cost-effectiveness analysis for all new treatements approved for routine use based on national economical model. Eribuline, a new anti-microtubule inhibitor got approval for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after an anthracycline, a taxane and a capecitabine containing regimens. Methods: All patients treated by eribulin in the Franche Comte region were prospectively monitored to assess efficacy, safety and cost-effectiveness of this new treatment based on a cost minimization strategy. The following costs were taken into account: drug, consultation with a medical oncologist, eventual supportive treatments, hospitalizations for treatment administration or for management of serious adverse events and the healthcare travels. Results: Ninety patients were treated by eribulin between July 2006 and October 2013. The median age was 58 (ranges: 32-79). A median number of 8 cycles (ranges 1 – 48) of eribulin...